Abbreviations: aGVHD = acute GVHD; ATG = anti-thymocyte globulin; Cy = cyclophosphamide; BDP = beclomethasone dipropionate; Bu = busulfan; BUD = budesonide; Clo = clofarabine; DLBCL = diffuse large B-cell lymphoma; Flu = fludarabine; GI = gastrointestinal; HL = Hodgkin's lymphoma; Methylpred = methylprednisolone; MMF = mycophenolate mofetil; MUD = matched unrelated donor; mMRD = mismatched related donor; mMUD = mismatched unrelated donor; MRD = matched related donor; NHL = non-Hodgkin lymphoma; PBSC = peripheral blood stem cells; Photo = photopheresis; Pred = prednisone; Pt = patient; T = tacrolimus; TBI = total body irradiation.
Pneumatosis intestinalis (PI) is characterized by the accumulation of gas in the intestinal wall. It is not considered to be a disease itself, but rather a pathologic and radiographic finding. PI is associated with various disorders including chronic obstructive pulmonary disease, autoimmune disorders and solid organ transplantation. 1, 2 The radiographic imaging is diagnostic, showing air-filled bullae along the intestinal border and occasionally a pneumoperitoneum. 3 PI has been observed and reported after allogeneic hematopoietic SCT (alloHSCT). [3] [4] [5] [6] [7] The occurrence of PI in this setting is thought to be associated with chemotherapy, acute GVHD (aGVHD), immunosuppression and infections. As symptoms of PI may mimic gastrointestinal aGVHD (GI-aGVHD), PI is frequently diagnosed incidentally during imaging performed to evaluate GI-aGVHD. We describe a series of 16 patients presenting with PI after alloHSCT. The majority of our patients had GI-aGVHD treated with prednisone and non-absorbable oral steroids beclomethasone dipropionate (BDP) and budesonide (BUD). We discuss the possible role of systemic steroids, as well as BUD, in the development of PI.
We retrospectively searched our radiology database for the images obtained by performing computerized tomography (CT) on patients who underwent alloHSCT from January 2005 to September 2013. Search terms included 'pneumatosis', 'pneumatosis intestinalis' and 'pneumatosis cystoides intestinalis'. An extensive chart review was performed on identified cases for the information on age, gender, diagnosis, conditioning chemotherapy, type of transplant, stem cell source, aGVHD, immunosuppression, CMV status and Clostridium difficile infection. In addition, the onset, management and outcome of PI were recorded. Approval for the study was obtained from our Institutional Review Board. During that time period, 1288 patients underwent alloHSCT at our institution. Sixteen patients were diagnosed with PI at a median of 108 days after alloHSCT (range, 25-578). Three cases of PI were identified between 2005 and 2010 (for 900 alloHSCT performed) and 13 cases between 2010 and 2013 (for 388 alloHSCT performed). This represents a statistically significant increase in the incidence of PI using Fisher's exact test (P o 0.0001). All patients had aGVHD at the time of PI diagnosis: 15 patients had GI +/ − skin aGVHD and 1 patient had liver-only aGVHD. Two of the patients who developed PI late after alloHSCT have received donor lymphocyte infusion 2 months prior to PI development and two additional patients had a biopsy-proven GIaGVHD. Fifteen patients were receiving systemic steroids at the time of PI diagnosis and 11 were also on BUD +/ − BDP. Nobody had active C. difficile or CMV colitis. Twelve patients had evidence of intraperitoneal or extraluminal free air, however, without clinically evident peritonitis. All patients were managed conservatively with bowel rest, total parenteral nutrition, antibiotics, temporary discontinuation of BUD/BDP and the reduction of prednisone dose. On repeated imaging, 11 patients had resolution of PI, 2 had significant improvement and 3 had no repeated imaging. Ten patients have died at the median of 72 days (range, 7-798) after PI diagnosis: six had documented resolution of PI, two had documented improvement and two had no repeated imaging prior to death. Patients and transplant characteristics are shown in Tables 1 and 2 . Although our study is observational and the findings are mainly confirmatory, this is the largest reported series of patients developing PI after alloHSCT and the first report describing the possible role of BUD in the development of PI. It has become a common practice to add non-absorbable oral steroids, BDP and BUD, to the treatment of patients with GI-aGVHD. 8, 9 Both drugs have a high affinity for the local steroid receptors, are rapidly metabolized by the intestinal cells and have a low bioavailability. BDP is predominantly distributed to the upper GI tract, while BUD works primarily in the ileocolonic region. Steroids that work at the level of bowel mucosa interfere less with the beneficial graftversus-tumor effect compared to systemic immunosuppression. The potential mechanism for developing PI after alloHSCT is that chemotherapy and immunosuppression induce atrophy of the Peyer's patches, leading to the loss of structural integrity of the bowel mucosa and subsequent gas migration into the submucosal and subserosal regions. Mucosal injury and increased intraluminal pressure in the setting of GI-aGVHD could be an additional contributing factor. Another hypothesis is that gas-forming bacteria invade the bowel wall, producing intramural gas. Steroids have known immunosuppressive properties, predispose to infection and inhibit wound healing. In several preclinical studies, both prednisone and BUD have been found to inhibit intestinal epithelial cell restitution and proliferation in vitro. 10 Both of these processes play an important role in rapid epithelial healing following intestinal injury. It is possible that BUD, in addition to prednisone, contributes to the reduced epithelial healing in these patients. Even though we saw a significant increase in the incidence of PI after we began to use BUD for GI-aGVHD, these results should be interpreted with caution. It is possible that the increase in incidence of PI after 2010 is due to the higher utilization CT imaging and better supportive care of patients with aGVHD with lower early mortality. Although patients with PI are frequently asymptomatic, some of the presenting symptoms may be diarrhea, intestinal bleeding, bloating, cramping or pain, mimicking GI aGVHD. CT scan is the most sensitive and specific radiographic test to diagnose PI; however, it does not have prognostic implications. 3, 5 The presence of pneumoperitoneum in these patients does not suggest a full mucosal perforation, but rather a rupture of a pneumatocele. None of our patients required surgical intervention or had a fatal outcome secondary to PI. There is no increased morbidity and mortality in patients with aGVHD who had PI compared with those without PI. Historically, the mortality in patients with PI has been associated with surgical complications rather than peritonitis or septic shock. Although it is possible that discontinuation of BUD might have had a beneficial effect on resolution of PI findings, improvements in PI could be due to the self-limiting nature of PI. Awareness about the existence of this condition is of paramount importance in providing appropriate conservative therapy and minimizing unnecessary surgical interventions. Abbreviations: aGVHD = acute GVHD; CT = computerized tomography; D = day; PI = pneumatosis intestinalis; Pt = patient; No CT = no repeated CT imaging.
Letter to the Editor
